Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03685591 · ClinicalTrials.gov registry record · Phase 1
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03685591 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 49 participants.
The verdict
NCT03685591, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
Interventions
- DRUG Enzalutamide
- DRUG PF-06952229
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03685591
The ClinicalTrials.gov registry entry for NCT03685591 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enzalutamide is the first listed.
NCT03685591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03685591 about?
NCT03685591 is a clinical study titled "PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors". A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
What is the current status of trial NCT03685591?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-10-04. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT03685591?
The interventions under investigation include: Enzalutamide (DRUG), PF-06952229 (DRUG).
Who is sponsoring clinical trial NCT03685591?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.